Listed by the USPTO as JONES, DAMERON LEVEST
Tech Center 3900 • Art Units: 1618 3991
This examiner grants 68% of resolved cases
JONES, DAMERON LEVEST works in tech center 3900 and art unit 1618. His profile records 1086 resolved cases, a 67.8% allowance rate, and a median of 1269 days to allowance. The 31.0% interview lift is substantial, indicating that interviews were associated with materially better allowance outcomes in the recorded matters. Interview preparation should therefore be considered an important part of response planning.
Listed companies include The Regents of the University of California, Board of Regents of the University of Texas System, and Harmony Foods LLC. Listed firms include Kilpatrick Townsend & Stockton LLP - West Coast, Knobbe, Martens, Olson & Bear, LLP, and THOMAS | HORSTEMEYER, LLP. The large case volume supports the profile as a meaningful reference. The moderate allowance rate and long median timing make disciplined amendment strategy and early issue identification especially useful.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18039301 | ROOM-TEMPERATURE PHOSPHORESCENCE NANOPARTICLES AND METHODS OF MAKING THE SAME | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF MICHIGAN |
| 17602689 | PROGRAMMABLE POLYMERIC DRUGS | Non-Final OA | SONY GROUP CORPORATION |
| 17873980 | IN SITU FORMING COMPOSITE MATERIAL FOR TISSUE RESTORATION | Non-Final OA | The Johns Hopkins University |
| 18716761 | CLOSO-DODECAIODODECABORATE COMPLEXES AND METHODS OF USE FOR SAME | Non-Final OA | The Regents of the University of California |
| 17630286 | CELL PENETRATING PEPTIDE FUNCTIONALIZED PERFLUOROCARBON NANOEMULSION COMPOSITIONS AND METHODS FOR IMAGING CELL POPULATIONS | Final Rejection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17844456 | CYCLIC PEPTIDES AS PROTEIN TARGETING AGENTS | Non-Final OA | California Institute of Technology |
| 18041470 | TEXAPHYRIN DERIVATIVES FOR MANGANESE CHEMOTHERAPY, PHOTOACOUSTIC IMAGING, AND PHOTOTHERMAL THERAPY | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17905124 | METHODS AND COMPOSITIONS FOR TREATMENT OF APC-DEFICIENT CANCER | Non-Final OA | Board of Regents, The University of Texas System |
| 17730130 | REAGENTS AND METHODS FOR LABELING MOLECULES WITH ASTATINE ISOTOPES IN HIGHER OXIDATION STATES | Final Rejection | University of Washington |
| 18573604 | Compounds For Molecular Imaging of Collagen Turnover and Methods Using Same | Non-Final OA | The United States Government as represented by the Department of Veterans Affairs |
| 19216949 | RADIOLABELLING KIT AND METHOD FOR RADIOLABELLING | Final Rejection | Telix Innovations SA |
| 17741686 | ANTI-NUCLEOLIN AGENT-CONJUGATED NANOPARTICLES | Final Rejection | University of Louisville Research Foundation, Inc. |
| 18580274 | X-RAY OPAQUE FILLER MATERIAL, X-RAY OPAQUE DENTAL FILLER MATERIAL, METHOD FOR PRODUCING X-RAY OPAQUE FILLER MATERIAL, AND CURABLE DENTAL COMPOSITION | Non-Final OA | TOKUYAMA DENTAL CORPORATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy67.8% of resolved applications examined by Dameron Levest Jones were allowed (1,086 resolved cases), compared with 33.1% across Art Unit 1618 over the last five years.
This examiner's interview lift is +31.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Dameron Levest Jones took 1,269 days on average from filing to allowance.
Dameron Levest Jones examines applications in Art Unit 1618 in Tech Center 3900.
